[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervix-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervix-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,48,85,110,146,166,194,215,244,270,295,320,348,372,438,462,491,518,542,566,593,613,639,670,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100615550","uniting-trusted-community-messengers-to-improve-access-to-cervical-cancer-screening-in-rural-north-carolina-100615550",false,"NCT07294066","Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina","Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina Aim 3","Woman participants\n\nInclusion Criteria:\n\n* Resident of Lenoir County and 12 community.\n* have not received a Pap test within the last 3.5 years, or an HPV test in the last 5.5 years\n* female ≥ 30 to 64 years of age at time of recruitment\n\nExclusion Criteria:\n\n* 65 years of age or older had a hysterectomy,\n* history of cervical cancer,\n* plan to move from Lenoir County during the study period.\n\nCommunity partners participants\n\nInclusion Criteria:\n\n* community health workers\n* clinic staff\n* community-based organization staff.\n\nExclusion Criteria:\n\n• None",true,"FEMALE","30 Years","64 Years",{"count":22,"type":23},112,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this study is to test the feasibility and acceptability of a multi-level, community-engaged intervention to increase access to cervical cancer screening using human papillomavirus (HPV) self-collection (HPVSC) outreach among women living in a high-risk rural county and to improve navigation for follow-up screening.\n\nA one-group intervention evaluation design will be used to pilot test feasibility and acceptability and to assess the proportion of women who return HPVSC kits and test HPV-positive. At the community level, local community-based organizations (CBOs) will serve as HPVSC kit distribution sites. At the individual level, trained community health workers will work with CBOs to support women throughout the HPVSC process, including specimen collection, kit return, result notification, and follow-up clinic-based screening for women who test HPV-positive.",[29,30],"Cervix Cancer","Screen HPV-positive",[32,33,34,35],"Screening","rural","outreach","high risk","NOT_YET_RECRUITING","2026-06-22",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":23},"2026-07",{"date":44,"type":23},"2029-03",{"name":46,"class":47},"UNC Lineberger Comprehensive Cancer Center","OTHER",{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":72,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100634904","phase-2-adjuvant-5-fluorouracil-following-thermal-ablation-to-improve-hpv-treatment-outcomes-in-women-with-hiv-in-kenya-100634904","NCT07545746","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya : The ASCEND Trial","ASCEND","Inclusion Criteria\n\n* Women aged 25 years or older\n* Known HIV-positive status\n* On antiretroviral therapy (ART) for at least 60 days prior to enrollment\n* Positive HPV screening test screening result\n* Able to provide informed consent in English, Swahili, or Dholuo\n* Agree to use dual contraception during dosing phase if of childbearing potential\n* Planning to remain in study locale for duration of study (48 weeks) Exclusion Criteria\n* Current pregnancy or breastfeeding\n* History of anogenital cancer (cervical, vulvar, or anal)\n* Current use of immunosuppressive medications\n* History of total hysterectomy\n* Known allergy to 5FU\n* Medical comorbidity that would interfere with study participation\n* Unwilling or unable to use contraception during study participation","25 Years",{"count":58,"type":23},140,[60],"PHASE2","This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in Kenya. The trial will also assess the safety, adherence, and acceptability of 5FU. Starting four weeks after TA, participants will self-administer 5FU cream or matched placebo intravaginally once every other week for 12 applications, with clinic visits at weeks 2, 8, 16, 24, and 48 for evaluation. All participants will be followed up to 48 weeks.\n\nIt is hypothesized that, compared to placebo, 5FU will increase HPV clearance at 24 weeks and that the proposed dosing schedule will be safe, well-tolerated, and acceptable in this population. Together with data from other studies, this trial will provide evidence on the use of self-administered intravaginal 5FU to improve HPV treatment outcomes in WWH in low- and middle-income countries, where the burden of cervical cancer is highest.",[63,64,29,65,66,67,68,69,70,71],"HIV Infections","HPV Infection","CIN2","CIN3","CIN1","CIN","Cervical Intraepithelial Neoplasia Grade 3","Cervical Intraepithelial Neoplasia Grade 1","Cervical Intraepithelial Neoplasia Grade 2\u002F3",[73,74,75,76],"5-fluorouracil (5FU)","thermal ablation (TA)","placebo","intravaginal topical","2026-06-01",{"date":79,"type":40},"2026-06-02",{"date":42,"type":23},{"date":82,"type":23},"2028-03",{"name":46,"class":47},2,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":109},"100638010","clinic-vs-cliniccommunity-outreach-hpv-self-collection-to-increase-cervical-screening-in-women-living-with-hiv-100638010","NCT07624123","Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV","Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial (CASCADE-3001-B)","C-3001B-P-CS7","Clinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH.\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives\n\nInclusion Criteria for Medical Record Abstraction\n\n* Are living with Human Immunodeficiency Virus (HIV)\n* Are 25-49 years of age, or as recommended by the Zimbabwe National Screening Guidelines\n* Live in the catchment areas of or attend a study-eligible clinic\n* Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:\n* They have never undergone cervical cancer screening before, or\n* They have never undergone HPV-based testing before and are now due for Visual Inspection with Acetic Acid and Cervicography (VIAC), per national guidelines, or\n* They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and \u002For\n* They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia \\>1 year ago and have not had any follow-up cervical cancer screening since treatment.\n\nExclusion Criteria for Medical Record Abstraction\n\n* Have had their cervix removed\n* Are pregnant or \\\u003C6 weeks post-delivery\n* Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral\n* Have previously been treated for invasive cervical cancer","49 Years",{"count":95,"type":23},17734,[26],"This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.\n\nThe 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.\n\nFurther understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.\n\nWhile it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers (CHWs) is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.",[29,63,64],[100,101],"self-collection","screening","2026-05-28",{"date":104,"type":40},"2026-06-03",{"date":106,"type":23},"2026-06",{"date":82,"type":23},{"name":46,"class":47},1,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":129,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":109},"100496383","physical-activity-intervention-among-older-women-with-gynecologic-cancers-fit4treatment-100496383","NCT05743517","Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)","Patient-Tailored Physical Activity Intervention Among Older Women With Gynecologic Cancers Undergoing Chemotherapy (Fit4Treatment)","Inclusion Criteria:\n\n* Female; \\> 60 years of age\n* Diagnosis of endometrial\u002Futerine, ovarian, cervical or vulvar\u002Fvaginal cancer\n* Undergoing or planning to undergo any systemic treatment for a gynecologic malignancy (e.g., chemotherapy, immunotherapy, anti-angiogenic therapies, targeted therapies, etc.)\n* Willing to try to identify an exercise partner to participate with them, if needed\n* Fluent in English\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular disease or other major contraindications to physical activity\n* Active brain metastases\n* Cognitive or functional limitations that preclude a patient's ability to participate in the physical activity intervention\n* Pregnant women or prisoners","60 Years",{"count":119,"type":23},192,[26],"The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.",[123,124,125,126,29,127,128],"Ovary Cancer","Endometrial Cancer","Uterine Cancer","Cervical Cancer","Vulvar Cancer","Vaginal Cancer",[130,131,132,133,134,135],"behavioral intervention","physical activity","cancer outcomes","chemotherapy","systemic therapy","quality of life","RECRUITING","2026-05-27",{"date":139,"type":40},"2026-05-29",{"date":141,"type":40},"2023-09-15",{"date":143,"type":23},"2029-08-01",{"name":145,"class":47},"Northwestern University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":93,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":109},"100625876","clinic-vs-cliniccommunity-outreach-hpv-self-collection-to-increase-cervical-screening-in-women-with-hiv-100625876","NCT07428330","Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV","Comparison of Clinic-based Versus Clinic-plus Community Outreach-based Strategy Via HPV Self-Collection to Increase Uptake of Cervical Cancer Screening Among Women Living With HIV: a Cluster Randomized Trial","CASCADE3001A","Clinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH.\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives\n\nInclusion Criteria for Medical Record Abstraction\n\n* Are living with Human Immunodeficiency Virus (HIV)\n* Are 25-49 years of age, or as recommended by Uganda's Ministry of Health Cervical Cancer Prevention and Control Guidelines\n* Live in the catchment areas of or attend a study-eligible clinic\n* Are eligible for Human Papillomavirus (HPV)-based cervicovaginal testing either because:\n* They have never undergone cervical cancer screening before, or\n* They have never undergone HPV-based testing before and are now due for Acetic Acid (VIA), per national guidelines, or\n* They have previously undergone HPV-based testing, and are now due for follow-up HPV-based testing per national guidelines, and \u002For\n* They underwent ablative or excisional treatment for presumed or confirmed cervical dysplasia \\>1 year ago and have not had any follow-up cervical cancer screening since treatment.\n\nExclusion Criteria for Medical Record Abstraction\n\n* Have had their cervix removed\n* Are pregnant or \\\u003C3 months post-delivery\n* Were positive on their most recent cervical cancer screening test and referred for further evaluation or treatment, but did not complete their referral\n* Have previously been treated for invasive cervical cancer\n\nClinic Inclusion Criteria\n\n* Clinics selected for inclusion will include those clinics that provide Human Immunodeficiency Virus (HIV) care and distribute antiretroviral therapy (ART) to Women living with Human Immunodeficiency Virus (WLWH).\n* These clinics should also have the ability to collect their own data.\n* Such clinics could be supported by national programs and bilateral donor-funded initiatives",{"count":155,"type":23},7597,[26],"This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE) C3001-A trial aims to assess how the introduction of a community-health-worker-facilitated model, in addition to the existing static clinic-only model, influences the rates of cervical cancer screening uptake among women living with HIV (WLWH). This study involves offering human papillomavirus (HPV) self-collection for cervical cancer screening to eligible WLWH.\n\nThe 'CASCADE' Network is a clinical trials network aimed at improving cervical cancer screening, management, and pre-cancer treatment for WLWH, in various healthcare settings. The network will conduct implementation trials to improve the triage of HPV-positive WLWH, as well as algorithms to optimize access to and options for effective treatment. Trials will be conducted using a mixed-methods approach aimed at assessing implementation strategies and outcomes and their potential to integrate into existing health systems.\n\nFurther understanding of HPV-based community-based strategies to reach WLWH, and the acceptability, feasibility, appropriateness, and cost of these strategies will be valuable for cervical cancer screening programs serving WLWH. Inputs from various 'CASCADE' Clinical Sites (CS) regarding feasible screening outreach options available in their settings for WLWH have guided this study that focuses on evaluating a pragmatic HPV self-collection implementation model to improve access to screening.\n\nWhile it is clear that HPV self-collection is a highly acceptable and feasible screening option, creating opportunities to conduct self-collection in alternative venues outside the clinic premises, and with the guidance of and facilitation by trusted community healthcare workers is an important implementation strategy that needs to be evaluated and considered for its potential benefit. Studies have not yet evaluated a community-based approach for HPV self-collection kit distribution among WLWH - who may have different characteristics, preferences, and access to screening services than women not living with HIV. Providing WLWH with the option of receiving HPV self-collection kits in their own homes or other community-based settings ('community-based HPV self-collection') is a novel implementation strategy that could improve cervical cancer screening rates among eligible women. Therefore, this novel trial aims to evaluate the feasibility and effectiveness of implementing community-based HPV self-collection among WLWH.",[29,63,64],[101,100],"2026-05-26",{"date":102,"type":40},{"date":163,"type":40},"2026-02-03",{"date":82,"type":23},{"name":46,"class":47},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":109},"100638020","postoperative-hypofractionated-whole-pelvic-radiotherapy-in-cervical-and-endometrial-cancer-100638020","NCT07595224","Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer","PostOPerative HYPOfractionated Whole Pelvic Radiotherapy in Cervical (Cx) and Endometrial Cancer (PostOP HYPOCxE Trial) : A Phase II Non-inferiority Randomized Controlled Trial","PostOP HYPOCxE","Inclusion Criteria:\n\n1. Pathologically proven carcinoma of the uterine cervix; and carcinoma and carcinosarcoma of uterine corpus\n2. Hysterectomy (total abdominal hysterectomy, vaginal hysterectomy, total laparoscopic hysterectomy or radical hysterectomy) for cancer of the cervix or endometrium within 49 days prior to registration. Hence inadvertent surgery will be allowed for inclusion.\n3. Indicated for adjuvant EBRT from multidisciplinary team discussion.\n4. Non-metastatic stage according to FIGO 2018 for Cervical cancer and FIGO 2023 for Endometrial cancer and TNM guidelines from appropriate diagnostic workup 4.1 History\u002Fphysical examination within 45 days prior to registration 4.2 CT\u002FMRI\u002FPET-CT of abdomen\u002Fpelvis demonstrating the absence of distant metastasis, performed pre- or post-surgery within 90 days prior to registration 4.3 Chest x-ray or chest CT (or a PET\u002FCT) performed within 90 days prior to registration\n5. Age ≥18 years old with informed consent\n\nExclusion Criteria:\n\n1. Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin\n2. Small cell neuroendocrine cancer, melanoma, uterine sarcoma, and other rare cancers in the cervix and uterus\n3. Metastatic disease beyond intervertebral disc L2\u002F3 level\n4. Previous pelvic or abdominal radiotherapy\n5. Combination of preoperative chemotherapy or radiotherapy with surgery\n6. Contra-indications to EBRT","ALL","18 Years",{"count":177,"type":23},120,[26],"This study aims to evaluate a shorter course of postoperative pelvic radiotherapy in patients with cervical and endometrial cancer. The standard radiotherapy schedule usually requires many treatment sessions over several weeks, which can be burdensome for patients and may affect their ability to complete treatment.\n\nThis study will compare a shorter radiotherapy schedule (hypofractionated radiotherapy) with the standard schedule. Both treatments deliver a similar total radiation dose, but the shorter schedule reduces the number of hospital visits and overall treatment time.\n\nParticipants will be randomly assigned to receive either the shorter or standard radiotherapy after surgery. The study will evaluate side effects, treatment effectiveness, and quality of life. The goal is to determine whether the shorter treatment is as safe and effective as the standard approach.",[124,29],[126,124,182,183,184],"Hypofractionated Radiotherapy","Whole Pelvic Radiotherapy","Postoperative Radiotherapy","2026-05-12",{"date":187,"type":40},"2026-05-19",{"date":189,"type":40},"2026-03-11",{"date":191,"type":23},"2028-12-31",{"name":193,"class":47},"Siriraj Hospital",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":109},"100536554","phase-2-study-of-pembrolizumab-and-lenvatinib-in-metastatic-and-recurrent-cervix-cancer-lenpem-cervix-100536554","NCT06266338","Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)","A Phase 2A, Prospective, Open Label, Single Institution Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all the following criteria apply:\n\n1. Female participants who are at least 18 years of age on the day of signing informed consent.\n2. Histologically confirmed diagnosis of squamous, adenocarcinoma or adenosquamous cervical cancer, that is recurrent or metastatic.\n3. Prior therapy: May have received up to 2 prior lines of systemic chemotherapy in the setting of advanced, metastatic (Stage IVB) or recurrent cervical cancer. May have received prior checkpoint inhibitor for advanced, metastatic (Stage IVB) or recurrent cervical cancer. May have received prior bevacizumab or antiangiogenic agent for recurrent or metastatic cervical cancer,\n4. Include whether prior checkpoint inhibitor was used in first line setting or second line setting.\n5. Prior Radiation therapy will be allowed and not counted as a line of treatment.\n6. Prior chemotherapy used as radiation sensitizer (e.g. cisplatin) used as treatment during chemoradiation will be allowed and counted as a line of treatment.\n7. Female participants:\n\n   * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n   * Not a woman of childbearing potential (WOCBP)\n\n   OR\n\n   Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab or 30 days post lenvatinib whichever occurs last. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study intervention.\n   * A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.\n   * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n   * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n8. Participants must have a PD-L1 diagnostic test of primary or recurrent archival tumor tissue.\n9. Participants may have progressed on treatment with an anti-PD-1\u002FL1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all the following criteria:\n\n   1. Has received at least 2 doses of an approved anti-PD-1\u002FL1 mAb.\n   2. Has demonstrated disease progression after anti-PD-1\u002FL1 as defined by RECIST v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid clinical progression.\n   3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1\u002FL1 mAb.\n\n   i. Progressive disease is determined according to iRECIST.\n\n   ii. This determination is made by the investigator. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n10. Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.\n11. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n12. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n13. Archival tumor tissue sample or newly obtained \\[core, incisional or excisional\\] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.\n14. Have an Eastern Cooperative Oncology Group performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n15. Have adequate organ and marrow function as defined in the following table (Table 2). Specimens must be collected within 10 days prior to the start of study intervention.\n16. Criteria for known Hepatitis B and C positive subjects.\n\n    Hepatitis B and C screening tests are not required unless:\n    * Known history of HBV or HCV infection\n    * As mandated by local health authority\n17. Hepatitis B positive subjects\n\n    * Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n    * Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n18. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\n    \\- Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n19. Have adequately controlled BP with or without antihypertensive medications, defined as BP ≤150\u002F90 mmHg with no change in antihypertensive medications within 1 week prior to randomization.\n20. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n2. Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to allocation.\n3. Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids.\n\n   Note: 2 weeks or fewer of palliative radiotherapy for non-CNS disease, with a 1-week washout, is permitted.\n4. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n\n   Note: please refer to Section 4.9 for information on COVID-19 vaccines.\n5. Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.\n6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within seven days prior to the first dose of study drug.\n7. Known additional malignancy that is progressing or has required active treatment within the past five years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.\n8. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n10. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)\n11. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n12. Has an active infection requiring systemic therapy.\n13. Has a known history of Human Immunodeficiency Virus (HIV) infection.\n\n    Note: No HIV testing is required unless mandated by local health authority.\n14. Concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n    Note: Hepatitis B and C screening tests are not required unless:\n    * Known history of HBV and HCV infection\n    * As mandated by local health authority\n15. Has had major surgery within three weeks prior to first dose of study interventions.\n\n    Note: Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility.\n16. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n18. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n19. Has had an allogenic tissue\u002Fsolid organ transplant.\n20. Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.\n21. Has urine protein ≥1 g\u002F24 hours.\n\n    Note: Participants with proteinuria ≥2+ (≥100 mg\u002FdL) on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria.\n22. Has a LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO).\n23. Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation.\n\n    Note: The degree of proximity to major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage\u002Fnecrosis following lenvatinib therapy\n24. Prolongation of QTcF interval to \\>480 ms.\n25. Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.\n\n    Note: Medically controlled arrhythmia would be permitted.\n26. Gastrointestinal malabsorption or any other condition that might affect the absorption of Lenvatinib.\n27. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within three weeks prior to the first dose of study drug.",{"count":202,"type":23},30,[60],"The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab has any effect on slowing tumor growth in cervical cancer tumors.",[29,126],"2026-05-03",{"date":208,"type":40},"2026-05-06",{"date":210,"type":40},"2024-03-11",{"date":212,"type":23},"2027-10-31",{"name":214,"class":47},"University of Texas Southwestern Medical Center",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":109},"100614189","phase-2-hypofractionated-radiotherapy-for-the-treatment-of-locally-advanced-cervical-cancer-in-uganda-100614189","NCT07276360","Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","Phase II Randomized Non-Inferiority Trial of Hypofractionated Radiotherapy for Locally Advanced Cervical Cancer in Uganda","HypoRTCx-UG","Inclusion Criteria:\n\n* Females aged 18 years or older\n* Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix without prior treatment\n* Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3, IIA, IIB, IIIA, IIIB, or IIIC\n* Able to provide written informed consent in English, Luganda, Runyankole, or Lango\n* Willing to attend post-treatment follow-up for up to 12 months\n* Fit for concurrent chemotherapy with cisplatin\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2\n* Absolute neutrophil count ≥ 1,500 cells\u002Fmm\\^3 (1.5 x 10\\^9\u002FL)\n* Platelets ≥ 100,000 cells\u002Fmm\\^3 (100 x 10\\^9\u002FL)\n* Hemoglobin ≥ 9.0 g\u002FdL\n* Leukocyte count ≥ 4,000 cells\u002Fmm\\^3 (4.0 x 10\\^9\u002FL)\n* Creatinine clearance \\> 60 mL\u002Fmins, calculated using the Cockcroft-gault equation for women\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 times the upper limit of normal (ULN)\n* Total bilirubin \\\u003C 2 x ULN unless attributed to the use of antiretroviral therapy (ART)\n* HIV-positive participants must be on a stable ART regimen for at least 6 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Prior hysterectomy. Women with previous total or subtotal hysterectomy have no cervix, and hence the anatomical changes have an impact on the radiotherapy field, and dose prescriptions because they tend to have a higher risk for bowel toxicity from pelvic radiotherapy. Therefore, these women will be excluded due to the likely impact on the results of our study intervention\n* Clinical and\u002For radiological evidence of distant metastases\n* Prior pelvic or abdominal radiotherapy\n* Presence of bilateral hip prosthesis that could interfere with radiotherapy treatment\n* History of inflammatory bowel disease or any other condition that could complicate radiotherapy treatment\n* Participants who are pregnant at the time of enrollment. Pregnant women have a potential risk of radiation exposure to developing fetus, which may result in fetal malformations, growth retardation, or even fatal death. Secondly, their physiological changes alter the pharmacokinetics and pharmacodynamics of concurrent chemotherapy. Therefore, to protect the health of the mother and the unborn child, pregnant women will be excluded from the study. Patients who are found to be pregnant after enrollment will have the study procedures terminated\n* Concurrent untreated invasive malignancy\n* Uncontrolled concurrent medical\u002Fpsychiatric diagnosis that would limit compliance with study requirements\n* Uncontrolled HIV infection, especially HIV viral load \\> 2,000 copies\u002FmL\n* Participants with CD4 counts \\\u003C 200 cells\u002Fmm\\^3",{"count":224,"type":23},278,[60],"This phase II trial compares the effect of hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) when given in combination with cisplatin and brachytherapy in patients with stage IB3, II, or III cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. CFRT delivers the total dose of radiation over the amount of time according to standard practice. HFRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HFRT shortens treatment duration and may reduce costs and may improve the completion rates. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HFRT may be safe, tolerable, and\u002For as effective as CFRT when given in combination with cisplatin and brachytherapy in treating patients with stage IB3, II or III cervical cancer.",[126,29,228,229,230],"Cervical Adenocarcinoma","Cervical Small Cell Carcinoma","Cervical Adenosquamous Carcinoma",[232,233,234,235],"Cervical cancer","Radiotherapy","Hypofractionation","Uganda","2026-03-26",{"date":238,"type":40},"2026-03-27",{"date":189,"type":40},{"date":241,"type":23},"2029-01-02",{"name":243,"class":47},"Uganda Cancer Institute",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":253,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":109},"100479362","phase-2-glutaminase-inhibition-and-chemoradiation-in-advanced-cervical-cancer-100479362","NCT05521997","Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","Inclusion Criteria:\n\nPatients eligible for definitive chemoradiotherapy, including brachytherapy\n\n* Patient age ≥ 18 years.\n* Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous, adenosquamous, adenocarcinoma or poorly differentiated); Federation of Gynecology and Obstetrics (FIGO) 2018 clinical stages III-IVA.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Absolute neutrophil count ≥ 1,500\u002FmcL.\n* Platelets ≥ 100,000\u002FmcL.\n* Hemoglobin ≥ 8 g\u002FdL (can be transfused prior to study).\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); patients with known Gilbert disease with serum bilirubin ≤ 3 x ULN may be enrolled.\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]\u002Falanine aminotransfersase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\] ≤ 2.5 x ULN.\n* Alkaline phosphatase ≤ 2.5 x ULN.\n* Serum creatinine ≤ 1.5 mg\u002FdL to receive weekly cisplatin; patients whose serum creatinine is between 1.5 and 1.9 mg\u002FdL are eligible for cisplatin if there is no hydronephrosis and the estimated creatinine clearance (CCr) is ≥ 30 ml\u002Fmin. For the purpose of estimating the CCr, formulas, including Cockcroft and Gault for females or similar, should be used.\n* International normalize ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular weight heparin or warfarin, should be on a stable dose).\n* Patient does not have uncontrolled diabetes mellitus (i.e. fasting blood glucose \\>200 mg\u002FdL).\n* Patient does not have a known allergy to cisplatin or compounds of similar biologic composition as CB-839.\n* Patient is not actively breastfeeding (or has agreed to discontinue before the initiation of protocol therapy).\n* Ability to understand and the willingness to sign a written informed consent document.\n* Patients does not have known human immunodeficiency virus syndrome (HIV testing optional).\n\nExclusion Criteria:\n\n* Patient has another concurrent active invasive malignancy.\n* Patient has received prior radiation therapy to the pelvis or previous therapy of any kind for this malignancy, or pelvic radiation for any prior malignancy.\n* Patient is receiving another investigational agent for the treatment of cancer.\n* Poorly controlled diabetes, with inability to perform 18F-FDG PET scan.\n* Patient is pregnant or breastfeeding.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Mean resting QTc \\> 470 msec obtained by electrocardiogram (ECG).\n* Severe, active co-morbidity defined as follows:\n\n  * Current (within 28 days of cycle 1, day 1) signs and\u002For symptoms of bowel obstruction\n  * Patients who require parental hydration and\u002For nutrition\n  * Patients who require drainage gastrostomy tube\n  * Evidence of bleeding diathesis or clinically significant coagulopathy\n  * Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\n  * History of hemoptysis (\\>= 1\u002F2 teaspoon of bright red blood per episode) within 1 month of study enrollment\n  * Significant cardiovascular or cerebrovascular disease including: Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\>= 150; diastolic blood pressure \\[DBP\\] \\>= 90)",{"count":252,"type":23},42,[60],"Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.",[256,126,29,257],"Advanced Cervical Carcinoma","Cancer of the Cervix",[259,260],"advanced cervical cancer","Glutaminase Inhibitor","2026-03-12",{"date":263,"type":40},"2026-03-13",{"date":265,"type":23},"2026-07-31",{"date":267,"type":23},"2032-10-07",{"name":269,"class":47},"Washington University School of Medicine",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":109},"100626437","late-radiation-toxicities-in-cervical-and-endometrial-cancer-a-postoperative-imrtbrachytherapy-study-100626437","NCT07435623","Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT\u002FBrachytherapy Study","Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and\u002For Brachytherapy","Inclusion Criteria:\n\n* Patients more than 18 years of age at the time of diagnosis.\n* All patients with confirmed histological diagnosis of cervical or endometrial cancer.\n* Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and\u002For brachytherapy at TMH\u002FACTREC will be included.\n* Patients whose follow up information available\n\nExclusion Criteria:\n\n* Patients with incomplete treatment details.\n* Patient having residual disease post-surgery.\n* Patient treated for post-operative recurrences.\n* Patient who lost to follow up.\n* Patients with Immunosuppressive disorder","75 Years",{"count":279,"type":23},300,"OBSERVATIONAL","Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical cancer (Stage IB1-IIA) includes chemo-radiation or surgery +\u002F- adjuvant (CT)RT and VBT if indicated. The choice of adjuvant treatment relies on identifying specific risk factors. Patients fulfilling Sedli's intermediate-risk criteria, requires pelvic radiotherapy alone and patients with high-risk Peter's criteria, require adjuvant chemoradiation. This risk-based approach helps tailor adjuvant therapies to individual patient.\n\nIndia reported 16,413 new cases and 6,385 deaths of endometrial cancer, with a mortality rate of 0.73%. The primary treatment for endometrial carcinoma is total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The Adjuvant treatment depends on risk stratification group according to ESGO\u002FESTRO\u002FESP guidelines determined through molecular-based risk stratification. Adjuvant treatment includes radiotherapy, chemotherapy, and brachytherapy.\n\nTo reduce the burden of acute and late toxicity, advanced external radiation techniques like image guided intensity modulated radiotherapy (IG IMRT) are used. IG IMRT have shown their potential to reduce late toxicity in long term survivors compared to 3DCRT technique. Since January 2020, our institution (TATA memorial centre, Mumbai) has incorporated routine IG-IMRT (Image-Guided Intensity-Modulated Radiation Therapy) for treatment of cervical and endometrial cancer. However, no post-implementation assessment of treatment outcomes and potential toxicity has occurred. This is retrospective observational study aims to evaluate the clinical application of IG-IMRT.\n\nPrimary aim of this study is to audit the 3 years incidence of ≥ grade II Gastrointestinal \\& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) between January 2020 to June 2023",[124,29],[284],"Cervical Cancer, Endometrical Cancer ,Gastrointestinal & Genitourinary toxicities","2026-02-26",{"date":287,"type":40},"2026-03-02",{"date":289,"type":40},"2025-05-10",{"date":291,"type":23},"2026-08-25",{"name":293,"class":294},"Tata Memorial Hospital","OTHER_GOV",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":109},"100447115","development-of-clinically-high-efficient-platforms-for-individualised-treatment-of-cervix-cancer-100447115","NCT05102240","Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer","Developing Clinical High Efficiency Platforms for Individualised Treatment Through Integration of Advanced Radiation Technology, Quantitative Imaging and Molecular Biology and Machine Learning for Treatment of Cervix Cancer.","Inclusion Criteria:\n\nFor Aim 1 and Aim 3:\n\n* Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI\u002FCT images at the time of diagnosis and brachytherapy For Aim 2\n* Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.\n\nExclusion Criteria:\n\n1. Lack of disease or toxicity outcomes.\n2. Lack of images in the hospital database.","90 Years",{"count":304,"type":23},1800,"Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability\n\nHypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.",[29],[308,309,310,311],"Advanced Radiation Technology","Quantitative Imaging","Molecular Biology","Machine Learning","2026-02-18",{"date":314,"type":40},"2026-02-20",{"date":316,"type":40},"2022-02-24",{"date":318,"type":23},"2026-06-30",{"name":293,"class":294},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":174,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":330,"conditions":331,"keywords":337,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":109},"100623759","cervical-cancer-oligo-states-recurrence-metastasis-multicentre-outcomes-study-100623759","NCT07400809","Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retro-COSMOS","Inclusion Criteria:\n\n1. Cervical cancer with (induced) oligo-metastatic and\u002For oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials\u002Fstudies.\n2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.\n3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis\u002Foligo-recurrence and present with further oligo-progression.\n4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.\n\nExclusion Criteria:\n\n1. Gynaecological cancer other than cervical cancer.\n2. Persistent Poly-metastatic disease post systemic treatment\n3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials.\n4. No clinical follow up after treatment",{"count":329,"type":23},350,"Systemic chemotherapy with or without palliative radiation represents the current standard of care in patients with recurrent or metastatic cervix cancer. In addition, pelvic radiotherapy including brachytherapy is also recommended. There is no consensus on the treatment of metastatic site in patients with oligo-metastatic or oligo-recurrent cervix cancer. Also, it is not clear if addition of local treatment to systemic chemotherapy benefits all patients with metastatic disease or a select few with limited systemic disease burden. It's presently unclear which patients derive maximum benefit with integration of radiation at both primary and metastatic site, who develop infield recurrence if performing salvage surgery, locally directed treatments or re-irradiation in addition to systemic chemotherapy improves overall outcomes. The heterogeneity in clinical practice provides an important opportunity to develop a framework for data collection and future studies within such subgroup of patients. In this retrospective study, we aim to determine overall survival, Infield progression free survival, overall progression free survival, dose response relationship of nodal and visceral progressions, and within setting of re-irradiation (infield progressions), severe adverse events and toxicity, risk groups identification, a nomogram which correlates risk groups with expected outcomes, and framework for tissue collection for translational research Investigators will record the parameters in a predesigned proforma without including personal identifiers.",[332,333,233,29,334,335,336],"Chemotherapy","Treatment Compliance","Surgery","Recurrent","Metastasis",[338,339],"Recurrent and Metastatic Cervix Cancer","Oligo States","2026-02-12",{"date":342,"type":40},"2026-02-17",{"date":344,"type":40},"2023-08-23",{"date":346,"type":23},"2027-06-14",{"name":293,"class":294},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":109},"100615454","phase-1-hyaluronic-acid-based-gel-spacers-in-gynecologic-malignancies-100615454","NCT07292818","Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies","Feasibility Study of Novel Applications of Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgment of the investigator.\n* Age ≥ 18 years at time of consent.\n* Eastern Cooperative Oncology Group Performance Status of 0-2 or Karnofsky Performance Scale score of 50-100.\n* Histological or cytological evidence of cervical cancer. Only patients with cervical cancer who are planned for chemoradiotherapy with brachytherapy, except for individuals with known rectal invasion.\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy.\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated in the study).\n* Known allergy to hyaluronic acid-based products.\n* Known inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.",{"count":356,"type":23},14,[358],"PHASE1","This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care.\n\nThe primary goal is to assess feasibility. Other goals include determining whether gel placement can reduce radiation dose to nearby healthy organs (organs at risk, OAR) and improve delivery of the prescribed radiation dose to the tumor.\n\nIn cervical cancer, the radiation dose to the tumor is often limited by the risk of exposing nearby sensitive organs, such as the rectum, bladder, and other pelvic structures. Vaginal packing techniques and specialized devices are used to protect these organs and ensure effective treatment. Gel spacers are inserted before radiation therapy to create space between the rectum and the cervix, reducing radiation exposure to healthy tissue. Already widely used in prostate cancer treatment in the U.S., gel spacers may also help improve tumor control and reduce treatment-related toxicity in cervical cancer.",[29],[362,363,364],"radiotherapy","brachytherapy","gel spacer",{"date":366,"type":40},"2026-02-04",{"date":368,"type":40},"2026-02-02",{"date":370,"type":23},"2030-10-30",{"name":46,"class":47},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":398,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":437},"100517783","phase-1-a-dose-escalation-and-dose-expansion-study-of-intratumoral-onm-501-alone-and-in-combination-with-cemiplimab-in-patients-with-advanced-solid-tumors-and-lymphomas-100517783","NCT06022029","A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas","ON-5001","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign written informed consent before performance of any study procedures\n2. Age ≥ 18 years\n3. Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.\n4. Participants must have a minimum of one injectable and measurable lesion.\n5. Participants with prior Hepatitis B or C are eligible if they have adequate liver function\n6. Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load \\\u003C400 copies\u002FmL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells\u002FuL\n7. Adequate bone marrow function:\n8. Adequate liver function\n\nExclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).\n\n1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.\n2. Major surgery within 4 weeks before the first dose of study drug.\n3. Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.\n4. Prolongation of corrected QT (QTc) interval to \\>470 millisecond (ms) for males and females when electrolytes balance is normal.\n5. Females who are breastfeeding or pregnant at screening or baseline\n6. Females of childbearing potential that refuse to use a highly effective method of contraception.\n7. Has uncontrolled or poorly controlled hypertension as defined by a sustained BP \\> 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.\n8. Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501\n9. Has an active infection requiring systemic treatment\n10. Is participating in another therapeutic clinical trial\n\nAdditional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)\n\n1. Has known hypersensitivity to any component in the formulation of cemiplimab\n2. Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\\>10 mg daily prednisone equivalent)\n3. Has a condition requiring systemic treatment with corticosteroids",{"count":381,"type":23},168,[358],"A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and\u002For recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.",[385,386,387,388,389,390,391,29,392,393,394,395,396,397],"Triple Negative Breast Cancer","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Lymphoma, Non-Hodgkin","Mantle Cell Lymphoma","Bladder Cancer","Uveal Melanoma, Recurrent","Carcinoma in Situ","Head and Neck Squamous Cell Carcinoma","Skin Cancer","Metastatic Cancer","Tumor, Solid","Tumor Recurrence",[399,400,401,402,403,404,405,406,394,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426],"Solid tumors","Lymphoma","ONM-501","STING","Intra-tumoral","HNSCC","Breast Cancer","Melanoma","cemiplimab","Libtayo","DLBCL","bladder cancer","cervical cancer","metastases","immunotherapy","ICI","TNBC","Triple Negative","mTNBC","anti-PD-1 antibody","BRCA1","BRCA2","anti-PD-L1","uveal","NHL","Mantle Zone lymphoma","FL","stimulator of interferon genes","2025-12-18",{"date":429,"type":40},"2025-12-24",{"date":431,"type":40},"2023-10-13",{"date":433,"type":23},"2026-08-29",{"name":435,"class":436},"OncoNano Medicine, Inc.","INDUSTRY",16,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":24,"phases":447,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":4},"100611807","phase-1-alendronate-to-reduce-pelvic-insufficiency-fractures-in-cervical-cancer-patients-undergoing-chemoradiation-100611807","NCT07245381","Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","A Pilot Study to Investigate the Use of Alendronate to Reduce the Risk of Pelvic Insufficiency Fractures in Cervical Cancer Patients Treated With Chemotherapy and Radiation Therapy","Inclusion Criteria:Age: Patients must be 18 years of age or older.\n\n* Diagnosis:Patients diagnosed with non-metastatic cervical cancer stages IB2 to IVA, as per the FIGO staging system.\n* Treatment Plan: Patients scheduled to undergo definitive chemo-radiotherapy or adjuvant chemo-radiotherapy post-surgery.\n* Bone Health: No history of osteoporosis or previous treatment with bisphosphonates or other bone-modifying agents.\n* Pain Assessment: Patients experiencing bone pain or at risk of developing pelvic insufficiency fractures, despite current standard of care.\n* Recent Imaging: Patients must have undergone recent imaging (CT, PET, or MRI) within the last 3 months to confirm the absence of bone metastases.\n* Compliance: Patients must be able to comply with the study protocol and follow-up schedule. Psychological, familial, sociological, or geographical conditions that could hamper compliance need to be evaluated and discussed before trial registration.\n* Consent: Patients must provide written informed consent before participating in the study\n\nExclusion Criteria:Age: Patients under 18 years of age.\n\n* Performance Status: Patients with an ECOG Performance Status of 2, 3 or 4.\n* Bone Metastases: Presence of bone metastases.\n* Contraindications to Alendronate: Known contraindications to alendronate, such as esophageal disorders, inability to sit or stand upright for at least 30 minutes, severe renal impairment (creatinine clearance \\\u003C35 mL\u002Fmin), or hypersensitivity to any component of the product.\n* Concurrent Treatments: Patients receiving other concurrent treatment with bisphosphonates, denosumab, or other bone-modifying agents.\n* Special Populations: Pregnant or breastfeeding women, prisoners, and patients with major psychiatric illnesses that could interfere with adherence to study requirements.\n* Previous Treatment: Patients who have previously received radiotherapy to the pelvic region.",{"count":446,"type":23},65,[358,60],"Primary Objective\n\n\\- Proof of concept: To evaluate the efficacy of alendronate in preventing pelvic insufficiency fractures (PIFs) in cervical cancer patients treated with chemo-radiotherapy over the short and long term. This objective will assess both the immediate and sustained effects of the drug on bone integrity through periodic bone mineral density measurements and clinical assessment of fracture incidence.\n\nSecondary Objectives\n\n* To assess the safety and tolerability of alendronate: This will involve monitoring and documenting any acute and chronic side effects associated with alendronate use in this patient population, including but not limited to gastrointestinal issues, renal function impairment, and osteonecrosis of the jaw.\n* To document and analyze changes in quality of life: Using validated quality of life instruments, this objective will track changes in patient-reported outcomes, focusing on aspects such as pain levels, physical function, and overall well-being. This will help determine if the intervention not only prevents fractures but also contributes positively to the patients' quality of life during and after treatment.\n* To explore correlations between patient-specific factors and treatment efficacy: This objective aims to understand how variables such as age, cancer stage, previous treatment history, and baseline bone health might influence the effectiveness of alendronate in preventing PIFs and enhancing bone mineral density.",[29],[451,452,257],"Chemo-Radiotherapy","Alendronate","2025-11-17",{"date":455,"type":40},"2025-11-24",{"date":457,"type":23},"2025-12",{"date":459,"type":23},"2026-09",{"name":461,"class":294},"Dr. Itay GoorAryeh",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":24,"phases":472,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":109},"100595113","ultrasound-training-program-for-gynecologic-cancer-staging-in-residents-100595113","NCT07028229","Ultrasound Training Program for Gynecologic Cancer Staging in Residents","Development and Validation of an Ultrasound Training Program for Residents in Staging Gynecological Cancers (Ovarian Cancer, Endometrial Cancer and Cervical Cancer)","Ultra-teaching","Inclusion Criteria:\n\n* At least six gynecology residents who will regularly attend the ultrasound center daily, with overlapping shifts.\n* All patients with a diagnosis or suspected diagnosis of gynecological cancer, including ovarian, endometrial, and cervical cancers, will be included in the study and scanned by both residents and experts.\n* Signing of the informed consent by the participants.\n\nExclusion Criteria:\n\n* non-gynecology specialists, with attendance schedules at the center other than daily.\n* Failure to sign the informed consent by the participants.",{"count":471,"type":23},6,[26],"This is a prospective, interventional study aiming to develop and validate an ultrasound training program for gynecology and obstetrics residents, focused on the staging of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The program consists of theoretical lectures, practical hands-on sessions, and supervised clinical case evaluations over a six-month period. Residents will perform ultrasound examinations independently, which will be compared to those conducted by expert sonographers. The primary objective is to assess the learning curve of each trainee by evaluating diagnostic concordance with expert findings across specific staging parameters.",[475,476,124,29],"Medical Education","Ovarian Cancer",[478,479,480,481],"Resident Training","Learning Curve","Gynecologic Oncology","Transvaginal Ultrasound","2025-06-11",{"date":484,"type":40},"2025-06-19",{"date":486,"type":23},"2025-06-16",{"date":488,"type":23},"2025-12-30",{"name":490,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":109},"100479074","phase-1-a-clinical-study-of-cd70-targeted-car-t-in-the-treatment-of-cd70-positive-advancedmetastatic-solid-tumors-100479074","NCT05518253","A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced\u002FMetastatic Solid Tumors","A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years old, male or female;\n2. Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced\u002Fmetastatic solid tumor (positive tumor CD70 expression (tumor CD70 positive (IHC 3+) confirmed by histology or pathology));\n3. Failure or intolerance after standard treatment (disease progression or intolerance such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.), and there is currently no effective treatment;\n4. According to the RECIST version 1.1 standard, at least one target lesion with measurable diameter and evaluable, measurable lesions are defined as: extranodal CT scan long diameter ≥ 10mm, lymph node lesions CT scan short diameter ≥ 15mm, scan slice thickness Not larger than 5mm, and has not received local treatment;\n5. ECOG 0-2 points;\n6. The expected survival time is more than 12 weeks;\n7. No serious mental disorder;\n8. The function of important organs is basically normal:\n\n   1. Hematopoietic function: neutrophils\\>1.0×109\u002FL, platelets\\>75×109\u002FL, hemoglobin\\>80g\u002FL;\n   2. Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;\n   3. Renal function: serum creatinine≤2.0×ULN;\n   4. Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN);\n   5. Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN);\n   6. Oxygen saturation \\> 92% in non-oxygen state.\n9. Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;\n10. Subjects agree to use reliable and effective contraceptive methods for contraception (excluding safe period contraception) within 1 year after signing the informed consent form to receiving CAR-T cell infusion;\n11. Subjects or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.\n\nExclusion Criteria:\n\n1. Received anti-CD70 drug treatment before screening;\n2. Active\u002Fsymptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging-proven progression ≥4 weeks after the end of treatment before they can be enrolled;\n3. Received any of the following treatments prior to screening:\n\n   1. Participated in other interventional clinical studies before screening, including: the last use of unmarketed new drugs is less than 3 months before cell reinfusion, or the last use of marketed drugs is less than 5 half-lives from cell reinfusion;\n   2. Received anti-tumor therapy such as chemotherapy and targeted therapy within 2 weeks or at least 5 half-lives (whichever is shorter) before apheresis;\n   3. Received systemic corticosteroid therapy at doses greater than 10 mg\u002Fday prednisone (or equivalent doses of other corticosteroids) within 2 weeks prior to apheresis (inhalation or topical is allowed in the absence of active autoimmune disease Use steroids and adrenal corticosteroid replacement at doses greater than 10 mg\u002Fday of prednisone);\n   4. Received live attenuated vaccine within 4 weeks before screening;\n4. Active infection or uncontrollable infection requiring systemic treatment within 1 week before screening;\n5. Malignant tumors other than the target tumor within 3 years prior to screening, except for the following: malignant tumors that have received radical treatment and no known active disease within ≥ 3 years prior to enrollment; or adequately treated of non-melanoma skin cancers with no evidence of disease;\n6. Have any of the following heart conditions:\n\n   1. New York Heart Association (NYHA) stage III or IV congestive heart failure;\n   2. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;\n   3. Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration);\n   4. History of severe nonischemic cardiomyopathy.\n7. Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc.;\n8. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA titer test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; cytomegalovirus (CMV) DNA test positive;\n9. The subject has experienced venous thromboembolic events (eg: pulmonary embolism) and still needs anticoagulation therapy, or meets the following conditions: a. Bleeding with grades 3 to 4 for more than 30 days; b. venous thrombosis Sequelae (such as persistent dyspnea and hypoxia); (Note: although subjects with venous thrombosis but not meeting the above conditions can participate in the trial);\n10. Poorly controlled hypertension, defined as systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg (blood pressure values measured based on the average of 3 readings at least 2 minutes apart, blood pressure ≥ 150\u002F90 mmHg at initial screening is acceptable Antihypertensive treatment, screening can be performed if the blood pressure is less than 150\u002F90mmHg and well controlled after treatment);\n11. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving CAR-T cell reinfusion;\n12. Other investigators deem it inappropriate to participate in the study.",{"count":202,"type":23},[358],"This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced\u002Fmetastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.",[502,503,504,476,29],"Metastatic Tumor","Advanced Solid Tumor","Renal Cell Carcinoma",[506,507,508],"CAR-T","CD70","CD70-positive advanced\u002Fmetastatic solid tumors","2025-05-26",{"date":511,"type":40},"2025-05-31",{"date":513,"type":40},"2022-05-30",{"date":515,"type":23},"2027-05-30",{"name":517,"class":47},"Weijia Fang, MD",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":24,"phases":527,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":109},"100581580","evaluation-of-the-diagnostic-and-prognostic-value-of-immunohistochemical-markers-in-precancerous-lesions-of-the-cervix-100581580","NCT06852157","Evaluation of the Diagnostic and Prognostic Value of Immunohistochemical Markers in Precancerous Lesions of the Cervix","Evaluation Of The Diagnostic And Prognostic Value Of Immunohistochemical Markers In Precancerous Lesions Of The Cervix","Inclusion Criteria:\n\n* Patients with a diagnosis of CIN\u002FSIL undergoing cervical biopsy\u002Fconcussion whose tissue sample is archived at the Operative Unit of Pathological Anatomy and Histology\n* Obtaining written informed consent for the use of biological samples\n* Patients aged 18 years and over\n\nExclusion Criteria: none",{"count":526,"type":23},100,[26],"The study aims to evaluate the expression of certain proteins and their diagnostic and prognostic value in precancerous lesions of the cervix.",[29],[531,532],"cervix cancer","gynaecology","2025-02-26",{"date":535,"type":40},"2025-02-28",{"date":537,"type":23},"2025-02",{"date":539,"type":23},"2026-02",{"name":541,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":109},"100505023","prognostic-and-diagnostic-added-value-of-medical-imaging-in-gynecological-cancer-prodigyn-100505023","NCT05855941","Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)","Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)","PRODIGYN","Inclusion Criteria:\n\n* Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.\n* Known clinical FIGO stage.\n* \\>18 years old.\n* No other known current or previous malignancy within the last 10 years.\n\nExclusion Criteria:\n\n* Imaging findings suggestive of other primary malignancy.\n* Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or \"cancer abdominis\".\n* MRI incompatible devices or patient unable to undergo MRI.",{"count":177,"type":23},"The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:\n\n* Does advanced medical imaging predict survival?\n* Can advanced medical imaging improve radiotherapy target planning?\n* Are advanced medical imaging results associated with risk markers found in tumor tissue?\n\nParticipants will\n\n* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months.\n* Be subject to clinical follow-up for five years.",[29,124,553],"Epithelial Ovarian Cancer",[555,556,29,124,553],"Positron Emission Tomography-Computed Tomography","Magnetic Resonance Imaging","2024-12-10",{"date":559,"type":40},"2024-12-16",{"date":561,"type":40},"2023-05-23",{"date":563,"type":23},"2032-05",{"name":565,"class":294},"Region Västerbotten",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":24,"phases":575,"briefSummary":576,"conditions":577,"keywords":578,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":109},"100548111","minimally-invasive-simple-hysterectomy-in-low-risk-cervical-cancer-100548111","NCT06416748","Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer","LASH","Inclusion Criteria:\n\n* Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma of uterine cervix\n* FIGO 2018 stage IA2-IB1 (≤2cm) with depth of infiltration ≤10mm on conization specimen\n* FIGO 2018 stage IA2-IB1 (≤2cm) with depth of infiltration ≤50% at pre-conization MRI-scan or \"expert\" US-scan.\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Neuroendocrine, clear cell, serous carcinoma\n* Depth of infiltration \\>10 mm on conization specimen\n* Depth of infiltration \\>50% at pre-conization imaging\n* Cervical tumor \\>2 cm\n* Diagnosis on inadvertent hysterectomy\n* Neoadjuvant chemotherapy\n* Previous pelvic radiotherapy\n* Pregnant women\n* Contraindications to surgery\n* Lymph nodes \\>15 mm short axis\n* Fertility sparing treatment or desire\n* Recurrent cervical cancer\n* Time between cervical cancer diagnosis and hysterectomy \\>4 months if conization with tumor negative margins\n* Time between cervical cancer diagnosis and hysterectomy \\>3 months if conization with invasive tumor positive margins",{"count":574,"type":23},974,[26],"The rationale of the present study is to assess the safety of the minimally invasive surgery approach in patients meeting the SHAPE trial inclusion criteria.The SHAPE trial was designed to answer the clinical question of whether simple hysterectomy could be performed instead of radical hysterectomy in low-risk early stage cervical cancer but not the surgical approach. The favorable oncological outcome observed in SHAPE despite 75% of patients were treated with minimally invasive approach suggests that this approach may be safe. However, the trial was not designed to analyze oncological outcomes from surgical approach.",[126,29],[232,579,580,581,582,583,584],"Minimally invasive surgery in cervical cancer","Robotic surgery in cervical cancer","Laparoscopic surgery in cervical cancer","LACC trial","SHAPE trial","Low risk cervical cancer","2024-10-26",{"date":587,"type":40},"2024-10-29",{"date":589,"type":40},"2024-10-27",{"date":591,"type":23},"2030-07-01",{"name":490,"class":47},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":17,"sex":18,"minAge":600,"maxAge":117,"enrollmentInfo":601,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":109},"100565388","prevalence-of-abnormal-pap-smear-100565388","NCT06641531","Prevalence of Abnormal Pap Smear","Prevalence of Abnormal Pap Smear in Sohag University Hospital Outpatient Clinic","Inclusion Criteria:\n\n* Non pregnant sexually active women aged from 21 to 60 years old.\n* Patients who didn't have their pap smear done in last 3 years .\n* Patient who had previous abnormal pap smear and coming for follow up.\n\nExclusion Criteria:\n\n* Women who were diagnosed cervical cancer that was treated.\n* Women who underwent total hysterectomy.\n* Women who are pregnant.\n* Patients whose pap smear was done in last 3 years with reassuring results.","21 Years",{"count":279,"type":23},"This study aims to evaluate prevalence of abnormal Pap smear among sexually active women of reproductive age attending sohag university hospital outpatient clinic.",[29],"2024-10-12",{"date":606,"type":40},"2024-10-15",{"date":608,"type":40},"2024-10-01",{"date":610,"type":23},"2025-04-01",{"name":612,"class":47},"Sohag University",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":622,"conditions":623,"keywords":627,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":109},"100537939","the-gynecological-cancer-associated-thrombosis-gyncat-study-100537939","NCT06284343","The Gynecological Cancer Associated Thrombosis (GynCAT) Study","Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study","GynCAT","Inclusion Criteria:\n\n* Female sex;\n* Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);\n* Planned new line of systemic antineoplastic treatment;\n* Age of 18 years or older;\n* Accordance of Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);\n* Diagnosis of symptomatic VTE at the time of screening for enrollment.",{"count":304,"type":23},"GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.",[624,625,626,476,29,124,128],"Cancer-associated Thrombosis","Venous Thromboembolism","Gynecologic Cancer",[628,629,630,476,128,124,626],"Thrombosis","Venous thromboembolism","Cancer","2024-09-17",{"date":633,"type":40},"2024-09-19",{"date":635,"type":40},"2024-04-15",{"date":637,"type":23},"2026-09-30",{"name":490,"class":47},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":175,"maxAge":647,"enrollmentInfo":648,"targetDuration":4,"studyType":24,"phases":650,"briefSummary":652,"conditions":653,"keywords":655,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":669},"100497960","phase-3-adjuvant-chemotherapy-in-cfhpv-dna-plasma-positive-patients-a-biomarker-in-locally-advanced-cervical-cancer-100497960","NCT05764044","Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer","Adjuvant Chemotherapy in Cell-free Human Papillomavirus Deoxyribonucleic Acid (cfHPV-DNA) Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer (CC)","AddChemo","Inclusion Criteria:\n\n* International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3 to IVA will be included prospectively.\n* Previous standard treatment based on concomitant chemoradiotherapy regimen.\n* Karnofsky performance status score ≥70, with estimated life expectancy ≥12 weeks,\n* Immunocompetent,\n* Positive research for types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA in plasma at the end of chemoradiotherapy,\n* Proper hematological, liver and kidney functions. Inclusion criteria will include absolute neutrophils count ≥1.5 x 109\u002FL, platelets ≥100 x 10\u002FL, serum bilirubin ≤ 2.0 x upper limit of normal (ULN), calculated creatinine clearance ≥50 mL\u002Fmin and alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN.\n* Patients of child-bearing potential were obligated to use an approved contraceptive method during and for 3 months after the study;\n* Agree with research procedures, by signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Previous cervical cancer or other malignancies,\n* Pregnant women,\n* Inability to perform concurrent cisplatin based-chemoradiotherapy.\n* Tumors containing different HPV genotypes\n* Absence of anatomopathological examination to prove the diagnosis and\u002For staging examinations.","70 Years",{"count":649,"type":23},365,[651],"PHASE3","This study hypothesizes that patients who persist with cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) plasma expression at the end of standard treatment, can derive the benefit of using adjuvant chemotherapy in locally advanced cervical cancer (CC). After standard treatment based on concomitant chemoradiotherapy regime, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Patients who have positive research for plasma cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.",[126,29,654],"Cervix Neoplasm",[656,657,232,658,659],"Human papillomavirus","HPV","Circulating free DNA","Adjuvant chemotherapy","2024-07-28",{"date":662,"type":40},"2024-07-30",{"date":664,"type":40},"2024-03-27",{"date":666,"type":23},"2026-12-31",{"name":668,"class":47},"Hospital do Coracao",26,{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":277,"enrollmentInfo":677,"targetDuration":4,"studyType":24,"phases":679,"briefSummary":680,"conditions":681,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":687,"leadSponsor":689,"locationsCount":4},"100545561","phase-1-a-clinical-study-of-anti-cd70-ucar-t-in-relapsed-or-refractory-solid-tumors-100545561","NCT06383507","A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors","A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors","Inclusion Criteria:\n\n1. Ability to understand and sign a written informed consent documen；\n2. Age ≥18 years old, male or female；\n3. Histopathological confirmed advanced or metastatic solid tumors failed to at least second-line treatment or initially diagnosed advanced\u002Fmetastatic solid tumors that have no NCCN guideline recommended standard first-line therapy；\n4. Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced\u002Fmetastatic solid tumor (positive tumor CD70 expression (tumor CD70 positive (IHC 2+) confirmed by histology or pathology));\n5. At least one measurable lesion at baseline per RECIST version 1.1；\n6. The expected survival time is more than 12 weeks;\n7. ECOG 0-1 points;\n8. The function of important organs is basically normal:Hematopoietic function:\n\n   * Hematopoietic function: neutrophils ≥ 1.5×109\u002FL, platelets ≥ 90×109\u002FL, hemoglobin ≥ 90g\u002FdL;\n   * Renal function: serum creatinine≤1.5×ULN;\n   * WBC≥3.0×109\u002FL,\n   * Liver function: Total bilirubin ≤ 1.5×ULN(Except Gilbert syndrome), extrahepatic metastasis：ALT and AST ≤ 3.0×ULN (Nonhepatic metastasis：it can be relaxed to ≤ 5.0×ULN);\n   * coagulation function：INR≤1.5×ULN，APTT≤1.5×ULN\n9. Subjects agree to use reliable and effective contraceptive methods for contraception within 6 months after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);\n\nExclusion Criteria:\n\n1. Received anti-CD70 drug treatment before screening;\n2. Received anti-tumor therapy such as chemotherapy and targeted therapy within 2 weeks or at least 5 half-lives (whichever is longer) before Received;\n3. Received systemic corticosteroid therapy at doses greater than 10 mg\u002Fday prednisone (or equivalent doses of other corticosteroids) within 2 weeks prior to Received；\n4. Pregnant, lactating, or breastfeeding females;\n5. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA titer test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; cytomegalovirus (CMV) DNA test positive;\n6. Have any of the following heart conditions:\n\n   New York Heart Association (NYHA) stage III or IV congestive heart failure; Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment; Clinically significant ventricular arrhythmia, echocardiography showed cardiac ejection fraction\\\u003C50%,\n7. Active\u002Fsymptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging evidence of progression ≥ 4 weeks after the end of treatment before they can be enrolled;\n8. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;\n9. Vaccination within 14 days of study enrollment;\n10. Received live attenuated vaccine within 4 weeks before screening;\n11. Malignant tumors other than the target tumor within 3 years prior to screening, except for the following: malignant tumors that have received radical treatment and no known active disease within ≥ 3 years prior to enrollment;\n12. Other investigators deem it inappropriate to participate in the study.\n13. Serious or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, liver and kidney insufficiency or metabolic disease, central nervous system disease, etc",{"count":678,"type":23},18,[358],"This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns.",[502,503,504,476,29,393,682],"Nasopharyngeal Carcinoma","2024-04-22",{"date":685,"type":40},"2024-04-25",{"date":683,"type":23},{"date":688,"type":23},"2029-04-21",{"name":690,"class":47},"Zhejiang University",{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":695,"acronym":696,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":174,"minAge":175,"maxAge":4,"enrollmentInfo":698,"targetDuration":4,"studyType":280,"phases":4,"briefSummary":700,"conditions":701,"keywords":706,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":714,"completionDateStruct":716,"leadSponsor":718,"locationsCount":109},"100519285","mri-guided-radiotherapy-and-radiobiological-data-the-israr-database-irm-sequences-for-radiobiological-adaptative-radiotherapy-100519285","NCT06041555","MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)","ISRAR","Inclusion Criteria:\n\n* 18years old or older\n* diagnosed with prostate, kidney, cervix, head and neck cancer or glioblastoma\n* indication of external radiotherapy\n* treated with the Linac UNITY MRI guided radiotherapy at the centre hospitalier Lyon Sud des Hospices Civils de Lyon\n* agreement of the patient to participate\n* affiliated to a social security system\n\nExclusion Criteria:\n\npatient unable to keep a lying position during all the procedure\n\n* patient under law restriction\n* pregnant women or breastfeeding",{"count":699,"type":23},600,"The MRI linac Unity is a major technological evolution in radiotherapy combining a linear accelerator with a 1.5T MRI (radiological quality). It allows to target the target volume more precisely and to adapt the daily dose distribution according to variations in the position and volume of the tumor, critical organs and the tumor response. In many studies conducted in radiology, the analysis of specific MRI sequences, particularly in radiomics, aims to characterize tumors and their sensitivity to treatment. Initial data show that in radiotherapy, it would eventually be possible to characterize the radiosensitivity of healthy and tumorous tissues. With linac 1.5T MRI, the performance of selected MRI sequences, at each session, could make it possible to identify different levels of radiosensitivity within the tumour. The reproduction of these sequences on a daily basis could make it possible to follow the variations in radiosensitivity during the treatment. The final objectives would be: 1- to adapt the doses of radiotherapy to each session with a modulation of the dose according to the daily level of intra-tumor radiosensitivity, 2- to develop Artificial Intelligence (AI) tools allowing an analysis sequences and the generation of 3D maps of intra-tumor radiosensitivity, fast and suitable for carrying out a radiotherapy session.\n\nA first work carried out in collaboration with the CREATIS lab of the University Claude Bernard Lyon 1 (UCBL1) made it possible to generate maps of tissue oxygenation from sequences produced on the MRI linac Unity of the Hospices Civils de Lyon (T2\\* , IVIM, Carto T2 Multi Echo-Gradient). Hypoxia is known to be the first factor of tumor resistance to irradiation. A research program is structured in collaboration with UCBL1 in order to develop radiobiological adaptive radiotherapy approaches, based on 3D maps of intra-tumoral hypoxia and their variation during treatment. Several tumor locations were selected because of the preponderant place of MRI in tumor characterization: prostate, cervix, kidney, ENT and glioblastoma. Hypoxia is not the only factor of radioresistance. Changes in the microenvironment could also impact the sensitivity of tumor cells. The program will therefore also aim to optimize the maps initially based on hypoxia, by identifying other relevant factors to be taken into account to define intra-tumor sensitivity.",[702,703,704,705,29],"Prostate Cancer","Glioblastoma","Head and Neck Cancer","Kidney Cancer",[707,708,233,709,710,630],"LINAC","MRI","Mapping","Hypoxia","2024-02-16",{"date":713,"type":40},"2024-02-20",{"date":715,"type":40},"2024-01-08",{"date":717,"type":23},"2029-01-08",{"name":719,"class":47},"Hospices Civils de Lyon"]